New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities
The facility houses 33 reactors, comprising stainless steel and glass-lined varieties, with capacities ranging from 1.6 KL to 16 KL
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Harnessing advanced data analysis for early detection, prevention and better outcomes
Subscribe To Our Newsletter & Stay Updated